Behbahani Ali
SEC insider (Form 3/4/5 filer). CIK 0001613867. Director at CRISPR Therapeutics AG (CRSP) and 9 other issuers. 72 reported Form 4/5 transactions since Sep 2024; latest on Sep 18, 2026. Located in MENLO PARK, CA.
Companies Behbahani Ali has filed insider reports for
- CRISPR Therapeutics AG (CRSP): Director
- Black Diamond Therapeutics, Inc. (BDTX): Director
- Monte Rosa Therapeutics, Inc. (GLUE): Director
- Korro Bio, Inc. (KRRO): Director
- Nkarta, Inc. (NKTX): Director
- Arcellx, Inc. (ACLX): Director
- Trevi Therapeutics, Inc. (TRVI): 10% Owner
- SpyGlass Pharma, Inc. (SGP): Director, 10% Owner
- NeueHealth, Inc. (NEUE): 10% Owner
- Adaptimmune Therapeutics PLC (ADAP): Director
Behbahani Ali
CIK: 0001613867
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (11)
CRISPR Therapeutics AG
Black Diamond Therapeutics, Inc.
Monte Rosa Therapeutics, Inc.
Korro Bio, Inc.
Nkarta, Inc.
Arcellx, Inc.
Trevi Therapeutics, Inc.
SpyGlass Pharma, Inc.
NeueHealth, Inc.
Adaptimmune Therapeutics PLC
MBX Biosciences, Inc.
Discretionary Trading P&L
Holdings
Transaction History (72 total)
- Sep 18, 2026BDTX
Black Diamond Therapeutics, Inc.
AwardDirect7.7K shares at avg. $1.93$15K - Sep 17, 2026CRSP
CRISPR Therapeutics AG
ExerciseDirect30K shares at avg. $14.00$420K - Sep 17, 2026CRSP
CRISPR Therapeutics AG
SaleDirect13.7K shares at avg. $57.09$781K - Jul 1, 2026GLUE
Monte Rosa Therapeutics, Inc.
OtherIndirect15K shares- - Jul 1, 2026GLUE
Monte Rosa Therapeutics, Inc.
OtherIndirect1M shares- - Jul 1, 2026GLUE
Monte Rosa Therapeutics, Inc.
OtherIndirect15K shares- - Jun 26, 2026BDTX
Black Diamond Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
40K shares- - Jun 19, 2026BDTX
Black Diamond Therapeutics, Inc.
AwardDirect9K shares at avg. $1.66$15K - Jun 11, 2026GLUE
Monte Rosa Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
25.8K shares- - Jun 10, 2026KRRO
Korro Bio, Inc.
AwardDirectStock Option (Right to Buy)
14.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 18, 2026 | BDTX Black Diamond Therapeutics, Inc. | Award | 7,707 | $1.93 | $14,875 | Direct |
| Sep 17, 2026 | CRSP CRISPR Therapeutics AG | Exercise | 30,000 | $14.00 | $420,000 | Direct |
| Sep 17, 2026 | CRSP CRISPR Therapeutics AG | Sale | 13,679 | $57.09 | $780,935 | Direct |
| Jul 1, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Other | 15,000 | - | $0 | Indirect |
| Jul 1, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Other | 1,000,000 | - | $0 | Indirect |
| Jul 1, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Other | 15,000 | - | $0 | Indirect |
| Jun 26, 2026 | BDTX Black Diamond Therapeutics, Inc. | Award Stock Option (Right to Buy) | 40,000 | - | - | Direct |
| Jun 19, 2026 | BDTX Black Diamond Therapeutics, Inc. | Award | 8,961 | $1.66 | $14,875 | Direct |
| Jun 11, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Award Stock Option (Right to Buy) | 25,800 | - | - | Direct |
| Jun 10, 2026 | KRRO Korro Bio, Inc. | Award Stock Option (Right to Buy) | 14,677 | - | - | Direct |
1-10 of 72 transactions